Moderna Inc. MRNA shares,
fell 0.9% in pre-market negotiations on Friday after the company said it is seeking approval for its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. 4502,
Takeda has submitted the new drug order and will be tasked with importing and distributing the vaccine from the company based in Cambridge, Massachusetts. Takeda is also conducting the Phase 1/2 trial of the vaccine in adults at least 20 years of age; enrollment ended in February. If approved, Takeda will distribute 50 million doses of Moderna’s two-dose vaccine in Japan in the first half of 2021. Moderna’s shares rose 372.3% in the last 12 months, while the broader S&P 500 SPX,
rose 20.4%.
